Gyre Therapeutics Inc
GYRE
Get informed when a big investor buys or sells
+ FollowMarket Cap$573.23M
Close$
$-1.55
127.3% downside
Current Fair Value
127.3% downsideOvervalued by 127.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $573.23 Million |
|---|---|
| Enterprise Value | $539.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.06 |
| Beta | 5.28 |
| Outstanding Shares | 91,317,142 |
Return
| Return on Equity | -0.57% |
|---|---|
| Return on Assets | -0.35% |
| Return on Invested Capital | 19.50% |
Valuation & Multiples
| P/E Ratio | -85.84 |
|---|---|
| PEG | 33.58 |
| Price to Sales | 5.69 |
| Price to Book Ratio | 5.69 |
| Enterprise Value to Revenue | 4.61 |
| Enterprise Value to EBIT | 19.46 |
| Enterprise Value to Net Income | -939 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 8, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$31.61 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$26.49 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.74%▼ 0.02% |
|---|---|
| Total Invested | $23.75M▲ 0.57% |
| Investors Holding | 55▲ 12.00% |
ESG Score
No data
About Gyre Therapeutics Inc
35 employees
CEO: Nassim Usman catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clin...